Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et fase 1-studie for at evaluere sikkerheden, tolerabiliteten og immunogeniciteten af ​​UB-313 hos raske deltagere

2. november 2026 opdateret af: Axxium Life, Inc.

Et fase 1 randomiseret, dobbeltblindt, placebokontrolleret, første-i-menneske-studie til evaluering af sikkerheden, tolerabiliteten og immunogeniciteten af ​​UBITh® CGRP-immunterapi (UB-313) hos raske deltagere

This first in-human (FIH) study of UB-313, an anti-calcitonin gene-related peptide based immunotherapeutic candidate, is designed to assess the safety, tolerability, and immunogenicity of 4 selected UB-313 dose regimens in healthy adults.

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

This is a single-site, randomized, double-blind, placebo-controlled, multidose regimen, FIH study of UB-313, an anti-CGRP peptide-based immunotherapy candidate. The double-blind period will include dose escalation and cohort staggering for up to 4 planned dose levels of UB-313 or placebo in 4 cohorts of healthy participants. All eligible participants will be enrolled in the study for up to 44 weeks, consisting of IM injections of UB-313 or placebo at Week 0 (Baseline, Day 1), Week 4, and Week 12. The End of Treatment (EoT) is defined as Week 16, followed by a follow-up period up to Week 44.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

40

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Leuven, Belgien
        • Katholieke Universiteit Leuven

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 55 år (Voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Is a male or female aged 18 to 55 years old, inclusive, at time of informed consent.
  • Has a body mass index between 18 and 30 kg/m2, inclusive at Screening, and with a minimum weight of 50 kg.
  • Male participants and their partners of childbearing potential must commit to the use of highly effective contraceptives for the study duration and for at least 12 weeks after the last dose. Men must refrain from donating sperm during this same period.
  • Female participants must be of nonchildbearing potential, or, for women of childbearing potential, must be willing to practice highly effective contraception throughout the duration of the study and for at least 24 weeks following the last dose.
  • Other inclusion criteria apply

Exclusion Criteria:

  • Has a history of clinically significant medical or psychiatric conditions, which in the opinion of the Investigator may compromise the participant's safety or the scientific value of the study, posing an unacceptable risk to the participant or interfere with the participant's ability to comply with study procedures or abide by study restrictions.
  • Presents any concern by the Investigator regarding safe participation in the study or for any other reason (including contraindication to MRI) that the Investigator considers the participant inappropriate for participation in the study.
  • Has a recent history (within the past year of Screening) of migraine headache.
  • Has unsuitable skin characteristics for the dermal capsaicin challenge as determined by the Investigator.
  • Has not demonstrated at least a 100% increase in dermal blood flow following capsaicin challenge as part of Screening procedures and measured through laser speckle contrast imaging.
  • Other exclusion criteria apply

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: UB-313 Cohort 1

UB-313 100mcg administered by intramuscular (IM) injection at Week 0, Week 4 and Week 12

A synthetic peptide-based immunotherapy

Eksperimentel: UB-313 Cohort 2

UB-313 300mcg administered by IM injection at Week 0 and 100mcg at Week 4 and Week 12

A synthetic peptide-based immunotherapy

Eksperimentel: UB-313 Cohort 3

UB-313 300mcg administered by IM injection at Week 0, Week 4 and Week 12

A synthetic peptide-based immunotherapy

Eksperimentel: UB-313 Cohort 4

UB-313 600mcg administered by IM injection at Week 0 and 100mcg at Week 4 and Week 12

A synthetic peptide-based immunotherapy

Placebo komparator: Placebo Comparator

Placebo (normal saline), administered by IM injection at Week 0, Week 4 and Week 12

Normal saline

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Participants With Treatment-Emergent Adverse Events
Tidsramme: 44 weeks

The number and percentage of participants with TEAEs were tabulated.

44 weeks
Immunogenicity Measured by Serum Anti-CGRP Antibodies.
Tidsramme: Weeks 0, 1, 4, 5, 8, 12, 13, 16, 20, 28, 36 and 44; Week 0, Week 16 and Week 44 are reported

Immunogenicity measured by blood anti-CGRP antibody titers, reported as Optical Density (OD) of 1:25 dilution.

Weeks 0, 1, 4, 5, 8, 12, 13, 16, 20, 28, 36 and 44; Week 0, Week 16 and Week 44 are reported

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Pharmacodynamics of the Immune Response Measured by Capsaicin-induced Increase in Dermal Blood Flow
Tidsramme: Weeks 0, 4, 8, 12, 16, 20

Number of Participants with inhibition of capsaicin-induced increase in dermal blood flow

Weeks 0, 4, 8, 12, 16, 20

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Medical Director, MD, Vaxxinity, Inc.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

6. juli 2022

Primær færdiggørelse (Faktiske)

6. oktober 2023

Studieafslutning (Faktiske)

6. oktober 2023

Datoer for studieregistrering

Først indsendt

20. juli 2022

Først indsendt, der opfyldte QC-kriterier

25. juli 2022

Først opslået (Faktiske)

28. juli 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

4. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner